Most people are deficient in vitamin D3. You can supplement with 2000, 5000, or 10,000 IU of vitamin D3 but that may not be enough. The only way to tell if your blood has an adequate amount of D3 is to have a blood test for D3 and have your doctor examine the results.
There is a lot of controversy and debate about whether you need to do a colon cleansing. Some say it is necessary and others say it's a waste of money and can do your body harm. You can imagine who it says it harms. Doctors say it's a waste of time and practitioners that offer a colon cleansing service cleansing say it is not. So who will you believe?
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
During the Academy of Nutrition and Dietetics 2017 Food & Nutrition Conference & Expo™ in Chicago, scientists reported on a recent study which uncovered that the intake of pistachios reduces the rise in blood sugar and insulin in women diagnosed with gestational diabetes mellitus (GDM)—commonly known as gestational diabetes. The study, “Effects of Pistachio Intake on Postprandial Blood Glucose Response in Pregnant Women,” found when women who were gestational glucose intolerant (GIGT) or who were diagnosed with GDM ate pistachios, they had a significantly lower rise in blood glucose levels compared to eating whole wheat bread that was matched for calories.
To view the multimedia release go to:
https://www.multivu.com/players/English/8162751-american-pistachio-growers-pistachio-health-benefits-women-gestational-diabetes/
As sleaze oozes from the Pentagon, banished Marine and Naval Academy alum Susanna Marcasi finds a web of corruption and must take on a man to whom all are beholden, Defense Secretary Manfred Stahl. Can she bring down the cloistered power brokers deep within the military’s superstructure and survive? Blood Stripe: The Susanna Marcasi Chronicles Find out more at – http://www.GinaMariaDiNicolo.com
Lustgarten Foundation funded researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have designed a multi-analyte blood test that can detect the presence of pancreatic cancer as part of a panel of eight common cancers (pancreas, ovary, liver, stomach, esophagus, colorectum, lung and breast) as reported in the online edition of Science today. The test utilizes combined assays for genetic alterations and protein biomarkers and has the capacity not only to identify the presence of relatively early cancer, but also to localize the organ of origin of these cancers.
“The potential this has for pancreatic cancer is unprecedented,” says Anne Marie Lennon, M.D., Ph.D., Associate Professor of Medicine, Director, Pancreatic Cyst Center of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center. “We know that in 80-85 percent of pancreatic cancer cases, it’s detected too late, leaving the patient with few options. Developing a blood screening test for pancreatic cancer has been an urgent goal, because catching the disease early will be the way we get to long-term survival.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213751-lustgarten-foundation-pancreatic-cancer-blood-test/
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7092251-fda-approve-s-exact-sciences-cologuard-screening-test-colorectal-cancer/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the ClearSight system.
The ClearSight system is a noninvasive monitor that provides clinicians access to valuable blood volume and blood flow information for patients at moderate or high risk of post-surgical complications, in whom invasive monitoring would not be used.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256451-edwards-fda-clearance-for-noninvasive-hemodynamic-monitoring-system/
Cigna (NYSE: CI) today unveiled its new TV Doctors of America campaign to encourage people to improve their health by going for their annual check-up, knowing their biometric numbers for blood pressure, cholesterol, blood sugar and body mass index (BMI), and taking control of their health. Supporting Cigna’s effort are actors Patrick Dempsey, Donald Faison, Neil Patrick Harris and Kate Walsh. All four actors starred as doctors on TV and are striking doctor poses, donning scrubs and using their celebrity influence to shine a spotlight on preventive care and the importance of going to a real doctor for an annual check-up that can help save lives.
To view the multimedia release go to:
https://www.multivu.com/players/English/8163851-cigna-americas-tv-doctors-go-know-take-control/
The Pharmaceutical Research and Manufacturers of America (PhRMA) today released new advertising as part of its “From Hope to Cures” campaign, highlighting the stories of rare blood and lung cancer survivors.
The newest video in the collection features Matt, who was diagnosed nearly seven years ago with advanced non-small cell lung cancer. When he was diagnosed, he was given a slim chance of living up to five years. However, today Matt continues to lead an active life due to recent advancements in targeted gene therapies and innovations in cancer medicines.
The latest print and digital ads feature Jamie, a vibrant woman diagnosed 15 years ago with chronic myelogenous leukemia (CML). Watching her son grow up was a primary focus for her, and she’s been able to continue to do that and so much more. Thanks to advancements in CML treatments, today she maintains her sense of humor and imparts an infectious joy on those who meet her.
Earlier this year, the first collection of digital and print ads was released featuring Rhys, a five-year-old living with type 1 diabetes and celiac disease. Unveiled alongside the advertising was a video, titled “We’re Fighting Back,” which features both Rhys and Jamie, as well as Jen, a researcher who wakes up every day working to find new treatments and cures for patients.
To view the multimedia release go to:
http://www.multivu.com/players/English/7738431-phrma-from-hope-to-cures/
Novartis announced today that the US Food and Drug Administration (FDA) has approved Jadenu™ (deferasirox) tablets, a new oral formulation of Exjade® (deferasirox) tablets for oral suspension, for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older, and chronic iron overload in non-transfusion-dependent thalassemia syndromes (NTDT) in patients 10 years of age and older. Jadenu is the only once-daily oral iron chelator that can be swallowed whole.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7440151-novartis-jadenu-fda-approval/
